The Role of Capecitabine in the Management of Tumors of the Digestive System

被引：7
作者：
Gennatas, Constantine [1 ]
Michalaki, Vasiliki [1 ]
Gennatas, Spyridon [2 ]
机构：
[1] Arete Hosp, Oncol Clin, Dept Surg, Athens, Greece
[2] Leicester Royal Infirm, Dept Cardiovasc Sci, Leicester, Leics, England
来源：
REVIEWS ON RECENT CLINICAL TRIALS | 2009年 / 4卷 / 01期
关键词：
Capecitabine; esophageal cancer; gastric cancer; gastroesophageal cancer; colorectal cancer; hepatic cancer; biliary tract cancer; gallbladder cancer; pancreatic cancer;
D O I：
10.2174/157488709787047576
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Capecitabine has been developed as a prodrug of FU, with the goal of improving tolerability and intratumor drug concentration through tumor-specific conversion to the active drug. The purpose of this article is to review the available information on capecitabine with respect to clinical efficacy for tumors of the digestive tract, adverse-effect profile, documented drug interactions, dosage and administration, and future directions of ongoing research. Relevant English-language literature was identified through searches of NCI, PubMed, ASCO. org and ESMO, ECCO meetings proceedings.
引用
收藏
页码：1 / 11
页数：11
相关论文
共 74 条
  • [1] Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer
    Adams, Richard
    Maughan, Tim
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2007, 7 (04) : 503 - 518
  • [2] Review of capecitabine as oral treatment of gastric, gastroesophageal, and Esophageal cancers
    Ajani, Jaffer
    [J]. CANCER, 2006, 107 (02) : 221 - 231
  • [3] Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: Feasibility, efficacy, and survival
    Allendorf, John D.
    Lauerman, Margaret
    Bill, Aliye
    DiGiorgi, Mary
    Goetz, Nicole
    Vakiani, Efsevia
    Remotti, Helen
    Schrope, Beth
    Sherman, William
    Hall, Michael
    Fine, Robert L.
    Chabot, John A.
    [J]. JOURNAL OF GASTROINTESTINAL SURGERY, 2008, 12 (01) : 91 - 100
  • [4] Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer
    Baek, J. H.
    Kim, J. G.
    Jeon, S. B.
    Chae, Y. S.
    Kim, D. H.
    Sohn, S. K.
    Lee, K. B.
    Choi, Y. J.
    Shin, H. J.
    Chung, J. S.
    Cho, G. J.
    Jung, H. Y.
    Yu, W.
    [J]. BRITISH JOURNAL OF CANCER, 2006, 94 (10) : 1407 - 1411
  • [5] Randomized multicenter phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma
    Bajetta, E
    Di Bartolomeo, M
    Mariani, L
    Cassata, A
    Artale, S
    Frustaci, S
    Pinotti, G
    Bonetti, A
    Carreca, I
    Biasco, G
    Bonaglia, L
    Marini, G
    Iannelli, A
    Cortinovis, D
    Ferrario, E
    Beretta, E
    Lambiase, A
    Buzzoni, R
    [J]. CANCER, 2004, 100 (02) : 279 - 287
  • [6] Blechacz B, 2008, 2008 AM SOC CLIN ONC
  • [7] Boni C, 2007, 43 AM SOC CLIN ONC A
  • [8] A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma
    Burge, ME
    Smith, D
    Topham, C
    Jackson, DP
    Anthoney, DA
    Halstead, F
    Seymour, MT
    [J]. BRITISH JOURNAL OF CANCER, 2006, 94 (09) : 1281 - 1286
  • [9] New approaches in systemic treatment of advanced colorectal cancer: the molecular targets era
    Capdevila, Jaume
    Mendez, Guillermo
    Macarulla, Teresa
    Ramos, Francisco Javier
    Casado, Esther
    Tabernero, Josep
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2007, 7 (07) : 1027 - 1041
  • [10] Cartwright TH, 2007, 43 AM SOC CLIN ONC A
12345678